Evidence map›Paper›PMID 24519092›Full record

ArticleBrazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica2014

Involvement of miR-30c in resistance to doxorubicin by regulating YWHAZ in breast cancer cells.

Y Fang, H Shen, Y Cao, H Li, R Qin, Q Chen, L Long, X L Zhu, C J Xie, W L Xu

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed, 1 pooled it
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 1 synthesis or guideline pooled it, 44 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Breast Cancer Response to Therapy: Can microRNAs Lead the Way?Journal of mammary gland biology and neoplasia · 2021
    Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Y FangDepartment of Central Laboratory, The First Affiliated People's Hospital, Jiangsu University, ZhenjiangJiangsu, China, Department of Central Laboratory, The First Affiliated People's Hospital, Jiangsu University, Zhenjiang, Jiangsu, China.
H ShenDepartment of Oncology, The First Affiliated People's Hospital, Jiangsu University, ZhenjiangJiangsu, China, Department of Oncology, The First Affiliated People's Hospital, Jiangsu University, Zhenjiang, Jiangsu, China.
Y CaoDepartment of Central Laboratory, The First Affiliated People's Hospital, Jiangsu University, ZhenjiangJiangsu, China, Department of Central Laboratory, The First Affiliated People's Hospital, Jiangsu University, Zhenjiang, Jiangsu, China.
H LiDepartment of Central Laboratory, The Fourth Affiliated People's Hospital, Jiangsu University, ZhenjiangJiangsu, China, Department of Central Laboratory, The Fourth Affiliated People's Hospital, Jiangsu University, Zhenjiang, Jiangsu, China.
R QinDepartment of Oncology, The First Affiliated People's Hospital, Jiangsu University, ZhenjiangJiangsu, China, Department of Oncology, The First Affiliated People's Hospital, Jiangsu University, Zhenjiang, Jiangsu, China.
Q ChenDepartment of Central Laboratory, The First Affiliated People's Hospital, Jiangsu University, ZhenjiangJiangsu, China, Department of Central Laboratory, The First Affiliated People's Hospital, Jiangsu University, Zhenjiang, Jiangsu, China.
L LongDepartment of Oncology, The First Affiliated People's Hospital, Jiangsu University, ZhenjiangJiangsu, China, Department of Oncology, The First Affiliated People's Hospital, Jiangsu University, Zhenjiang, Jiangsu, China.
X L ZhuDepartment of Central Laboratory, The Fourth Affiliated People's Hospital, Jiangsu University, ZhenjiangJiangsu, China, Department of Central Laboratory, The Fourth Affiliated People's Hospital, Jiangsu University, Zhenjiang, Jiangsu, China.
C J XieDepartment of Central Laboratory, The First Affiliated People's Hospital, Jiangsu University, ZhenjiangJiangsu, China, Department of Central Laboratory, The First Affiliated People's Hospital, Jiangsu University, Zhenjiang, Jiangsu, China.
W L XuDepartment of Central Laboratory, The Fourth Affiliated People's Hospital, Jiangsu University, ZhenjiangJiangsu, China, Department of Central Laboratory, The Fourth Affiliated People's Hospital, Jiangsu University, Zhenjiang, Jiangsu, China.
Jiangsu University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

MicroRNAs (miRNAs) are small RNA molecules that modulate gene expression implicated in cancer, which play crucial roles in diverse biological processes, such as development, differentiation, apoptosis, and proliferation. The aim of this study was to investigate whether miR-30c mediated the resistance of breast cancer cells to the chemotherapeutic agent doxorubicin (ADR) by targeting tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein zeta (YWHAZ). miR-30c was downregulated in the doxorubicin-resistant human breast cancer cell lines MCF-7/ADR and MDA-MB-231/ADR compared with their parental MCF-7 and MDA-MB-231 cell lines, respectively. Furthermore, we observed that transfection of an miR-30c mimic significantly suppressed the ability of MCF-7/ADR to resist doxorubicin. Moreover, the anti-apoptotic gene YWHAZ was confirmed as a target of miR-30c by luciferase reporter assay, and further studies indicated that the mechanism for miR-30c on the sensitivity of breast cancer cells involved YWHAZ and its downstream p38 mitogen-activated protein kinase (p38MAPK) pathway. Together, our findings provided evidence that miR-30c was one of the important miRNAs in doxorubicin resistance by regulating YWHAZ in the breast cancer cell line MCF-7/ADR.

Indexed as

Drug Resistance, NeoplasmAnimalsAntibiotics, AntineoplasticDoxorubicinEnzyme ActivationFemaleGene Expression Regulation, NeoplasticHumansInhibitory Concentration 50MCF-7 CellsMiceMicroRNAsTryptophan HydroxylaseTyrosine 3-MonooxygenaseAntibiotics, AntineoplasticDoxorubicinMicroRNAsMIRN30b microRNA, humanTryptophan HydroxylaseTyrosine 3-Monooxygenase

Identifiers

PMID24519092
PMCPMC3932974
OpenAlexW1852572532

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.